1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014; 37(Suppl 1):S81-90.
2. Ostergaard L, Mogensen UM, Bundgaard JS, Dahl A, Wang A, Torp-Pedersen C, et al. Duration and complications of diabetes mellitus and the associated risk of infective endocarditis. Int J Cardiol. 2019; 278:280-4.
3. Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson AM, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018; 379(7):
633-44.
4. Eileen Dolan M. Inhibition of DNA repair as a means of increasing the antitumor activity of DNA reactive agents. Adv Drug Deliv Rev. 1997; 26(2-3):105-18.
5. Vivek K. Streptozotocin: an experimental tool in diabetes and alzheimer’s disease (A-Review). Int J Pharma Res Dev. 2010; 2(1):1-7.
6. Rakeiten N, Rakieten ML, Nadkarni MV. Studies on the diabetogenic action of streptozotocin. Cancer Chemother Rep. 1963; 29:91-8.
7. Rerup CC. Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol Rev. 1970; 22(4):485-518.
8. Jin R, Jin Z, Cai H. Influence of electroacupuncture plus jasminoidia intervention on expression of OX-42 and nuclear factor-kappa B in hippocampus and amygdale in cerebral ischemia plus diabetes rats. Zhen Ci Yan Jiu. 2014; 39(4):305-12.
9. Holmes A, Coppey LJ, Davidson EP, Yorek MA. Rat models of diet-induced obesity and high fat/low dose streptozotocin type 2 diabetes: effect of reversal of high fat diet compared to treatment with enalapril or menhaden oil on glucose utilization and neuropathic endpoints. J Diabetes Res. 2015; 2015:307285.
10. Groop L, Groop PH, Stenman S, Saloranta C, Tötterman KJ, Fyhrquist F, et al. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care. 1987; 10(6):671-8.
11. Meier J, Gallwitz B, Schmidt W, Mügge A, Nauck M. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart. 2004; 90(1):9-12.
12. Zhang BB, Moller DE. New approaches in the treatment of type 2 diabetes. Curr Opin Chem Biol. 2000; 4(4):461-7.
13. Chatterjee S, Riewpaiboon A, Piyauthakit P, Riewpaiboon W, Boupaijit K, Panpuwong N, et al. Cost of diabetes and its complications in Thailand: a complete picture of economic burden. Health Soc Care Community. 2011; 19(3):289-98.
14. Autore G, Capasso F, De Fusco R, Fasulo M, Lembo M, Mascolo N, et al. Antipyretic and antibacterial actions of Teucrium polium (L.). Pharmacol Res Commun. 1984; 16(1):21-9.
15. Marble A. Glibenclamide, a new sulphonylurea: whither oral hypoglycaemic agents? Drugs. 1971; 1(2):109-15.
16. Ashcroft F. KATP channels and insulin secretion: a key role in health and disease. Biochem Soc Trans. 2006; 34(Pt 2):243-6.
17. Nichols CG. KATP channels as molecular sensors of cellular metabolism. Nature. 2006; 440(7083):470-6.
18. Mirbadalzadeh R, Shirdel Z. Antihyperglycemic and antihyperlipidemic effects of Cornus mas extract in diabetic rats compared with glibenclamide. Elixir (Hormo & Signal). 2012; 47:8969-72.
19. Simard JM, Woo SK, Schwartzbauer GT, Gerzanich V. Sulfonylurea receptor 1 in central nervous system injury: a focused review. J Cereb Blood Flow Metab. 2012; 32(9):1699-717.
20. Sarkarizi HK, Sazegar G, Rajabzadeh A. Effect of hydro-alcoholic teucrium polium L. extract and glibenclamide administration on blood glucose and lipid profile levels in streptozotocin-induced diabetic rats. Clin Res. 2015; 1(2):38-45.
21. Ashrafihelan J, Yazdanparast R, Esmaeili M, Nowrozi M. A pathologic study on changes of pancreas, liver and kidney due to Teucrium polium extract in streptozotocin induced-diabetic rats. Pharm Sci. 2010; 16(1):11-20.
22. Erejuwa OO, Sulaiman SA, Wahab MS, Sirajudeen KN, Salleh MS, Gurtu S. Glibenclamide or metformin combined with honey improves glycemic control in streptozotocin-induced diabetic rats. Int J Biol Sci. 2011; 7(2):244.
)